SEARCH

SEARCH BY CITATION

References

  • 1
    Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231264.
  • 2
    Shepard CW, Finelli L. Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558567.
  • 3
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 4
    Gothel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999; 55: 423436.
  • 5
    Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111122.
  • 6
    Bieniasz P. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004; 5: 11091115.
  • 7
    Sokolskaja E, Luban J. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol 2006; 9: 404408.
  • 8
    Inoue K, Umehara T, Ruegg UT, Yasui F, Watanabe T, Yasuda H, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. HEPATOLOGY 2007; 45: 921928.
  • 9
    Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. HEPATOLOGY 2006; 43: 761770.
  • 10
    Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch LA, Ward PA, et al. Naturally occuring capsid substitutions render HIV-1 cyclophilin a independent in human cells and trim-cyclophilin resistant in owl monkey cells. J Biol Chem 2005; 280: 4029340300.
  • 11
    Steyn D, Richman DD, Aeschlimann C, Dumont J-M, Grosgurin P, Rosenwirth B, et al. A double-blind placebo-controlled study in HIV-1-infected subjects on the safety, pharmacokinetics and antiviral effect of cyclophilin A targeting DEBIO-025. In: 13th Conference on Retroviruses and Opportunistic Infections (CROI). Denver, CO, February 5-8, 2006.
  • 12
    Koletsky AJ, Harding MW, Handschumacher RE. Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J Immunol 1986; 137: 10541059.
  • 13
    Brée F, Dumont J-M, Nicolas V, Tillement J-P. In vitro blood distribution and protein binding of a new anti-HIV drug, DEBIO-025. In: PharmSciFair, European Federation for Pharmaceutical Sciences (EUFEPS). Nice, France, June 12-17, 2005.
  • 14
    Price ER, Jin M, Lim D, Pati S, Walsh CT, McKeon FD. Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A. Proc Natl Acad Sci U S A 1994; 91: 39313935.
  • 15
    Denys A, Allain F, Masy E, Dessaint JP, Spik G. Enhancing the effect of secreted cyclophilin B on immunosuppressive activity of cyclosporine. Transplantation 1998; 65: 10761084.
  • 16
    Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A 2003; 100: 20142018.
  • 17
    Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • 18
    Pawlotsky J-M. Treatment of hepatitis C: don't put all your eggs in one basket! Gastroenterology 2007; 132: 16111614.
  • 19
    Allain F, Boutillon C, Mariller C, Spik G. Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies. J Immunol Methods 1995; 178: 113120.
  • 20
    Rice CM, You S. Treating hepatitis C: can you teach old dogs new tricks? HEPATOLOGY 2005; 42: 14551458.